AEterna Zentaris Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Markets Direct's, 'AEterna Zentaris Inc. - Product Pipeline Review - 2014', provides an overview of the AEterna Zentaris Inc. 's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AEterna Zentaris Inc. 's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AEterna Zentaris Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AEterna Zentaris Inc. 's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the AEterna Zentaris Inc. 's pipeline products

Reasons to buy

- Evaluate AEterna Zentaris Inc. 's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AEterna Zentaris Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AEterna Zentaris Inc. 's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AEterna Zentaris Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AEterna Zentaris Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AEterna Zentaris Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
AEterna Zentaris Inc. Snapshot 6
AEterna Zentaris Inc. Overview 6
Key Information 6
Key Facts 6
AEterna Zentaris Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
AEterna Zentaris Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
AEterna Zentaris Inc. - Pipeline Products Glance 12
AEterna Zentaris Inc. - Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
AEterna Zentaris Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
AEterna Zentaris Inc. - Early Stage Pipeline Products 16
IND/CTA Filed Products/Combination Treatment Modalities 16
Preclinical Products/Combination Treatment Modalities 17
AEterna Zentaris Inc. - Drug Profiles 19
macimorelin acetate 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
zoptarelin doxorubicin 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
miltefosine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ozarelix 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
perifosine 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AEZS-112 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AEZS-120 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AEZS-125 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AEZS-126 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AEZS-127 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AEZS-129 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AEZS-134 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AEZS-136 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AEZS-137 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AEZS-138 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AN-162 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AN-207 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AEterna Zentaris Inc. - Pipeline Analysis 44
AEterna Zentaris Inc. - Pipeline Products by Target 44
AEterna Zentaris Inc. - Pipeline Products by Route of Administration 46
AEterna Zentaris Inc. - Pipeline Products by Molecule Type 47
AEterna Zentaris Inc. - Pipeline Products by Mechanism of Action 48
AEterna Zentaris Inc. - Recent Pipeline Updates 50
AEterna Zentaris Inc. - Dormant Projects 62
AEterna Zentaris Inc. - Discontinued Pipeline Products 64
Discontinued Pipeline Product Profiles 64
AEZS-115 64
AEZS-123 64
AEZS-131 65
AEZS-132 65
AN-215 65
AN-238 65
miltefosine 65
ozarelix 66
perifosine 66
teverelix 66
zoptarelin doxorubicin 66
AEterna Zentaris Inc. - Company Statement 67
AEterna Zentaris Inc. - Locations And Subsidiaries 69
Head Office 69
Other Locations & Subsidiaries 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71

List of Tables
AEterna Zentaris Inc., Key Information 6
AEterna Zentaris Inc., Key Facts 6
AEterna Zentaris Inc. - Pipeline by Indication, 2014 8
AEterna Zentaris Inc. - Pipeline by Stage of Development, 2014 10
AEterna Zentaris Inc. - Monotherapy Products in Pipeline, 2014 11
AEterna Zentaris Inc. - Pre-Registration, 2014 12
AEterna Zentaris Inc. - Phase III, 2014 13
AEterna Zentaris Inc. - Phase II, 2014 14
AEterna Zentaris Inc. - Phase I, 2014 15
AEterna Zentaris Inc. - IND/CTA Filed, 2014 16
AEterna Zentaris Inc. - Preclinical, 2014 17
AEterna Zentaris Inc. - Pipeline by Target, 2014 45
AEterna Zentaris Inc. - Pipeline by Route of Administration, 2014 46
AEterna Zentaris Inc. - Pipeline by Molecule Type, 2014 47
AEterna Zentaris Inc. - Pipeline Products by Mechanism of Action, 2014 49
AEterna Zentaris Inc. - Recent Pipeline Updates, 2014 50
AEterna Zentaris Inc. - Dormant Developmental Projects,2014 62
AEterna Zentaris Inc. - Discontinued Pipeline Products, 2014 64
AEterna Zentaris Inc., Subsidiaries 69